Bio Farma President Director Shadiq Akasya stated that the company’s active involvement in DCVMN reflects Indonesia’s transformation from a recipient of global health technology to a contributor shaping international vaccine standards and innovation.
“The active participation of Bio Farma’s experts in DCVMN’s working groups demonstrates Indonesia’s commitment to driving innovation and setting new global benchmarks in vaccine development,” Shadiq said in a statement on Thursday.
He added that the company’s engagement represents a concrete step toward achieving equitable health independence and resilience.
As a driving force in vaccine collaboration among developing countries, Bio Farma’s experts have played an active role in several of DCVMN’s working groups, contributing their knowledge and experience to shape global vaccine policies and practices.
The Bio Farma experts involved include Rini Mulia Sari (Clinical Trial Working Group), Taufik Wilmansyah (Supply Chain Working Group), Acep Riza Wijayadikusumah (Design of Experiment Working Group), Viska Indriani (Co-Chair, Pharmacovigilance Working Group), Indra Gunawan Setiadi (Manufacturing Science Working Group), Irma Riyanti (3R/Replace, Reduce, Refine Working Group), and Dea Marsendah (Training Working Group).
The company also stated that its participation aims to strengthen collaboration, enhance capacity building, and promote equal access to safe and affordable vaccines for developing countries.
Bio Farma will co-host the 26th DCVMN Annual General Meeting (AGM) in Bali from October 29 to 31, 2025. The event will bring together vaccine producers and global health partners to discuss innovation, technology transfer, regulatory harmonization, and industry sustainability.
DCVMN CEO, Rajinder Suri, said the network recorded more than 115 collaborations between 2021 and 2025, including 41 South-South initiatives, reflecting the expanding role of developing nations in advancing vaccine self-reliance and innovation.
The DCVMN is a global alliance of 46 vaccine manufacturers from 17 developing countries, established in 2000 to strengthen public health through equitable access to high-quality vaccines. The network works closely with global health agencies including WHO, Gavi, CEPI, and UNICEF to enhance technical, regulatory, and research capacities across its members.
Related news: Bio Farma's participation in DCVMN contributes to global health
Related news: Bio Farma committed to develop vaccine independence, health resilience
Reporter: Martha Herlinawati Simanjuntak
Editor: Yuni Arisandy Sinaga
Copyright © ANTARA 2025
